secukinumab psoriatic arthritis
Selected indexed studies
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (Drugs Today (Barc), 2023) [PMID:36847624]
- Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. (Ann Rheum Dis, 2021) [PMID:33334727]
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. (Lancet, 2015) [PMID:26135703]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis. (2023) pubmed
- Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. (2021) pubmed
- Secukinumab: A Review in Psoriatic Arthritis. (2021) pubmed
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (2024) pubmed
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2015) pubmed
- Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. (2023) pubmed
- Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. (2020) pubmed
- Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis. (2023) pubmed
- Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. (2018) pubmed
- Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. (2022) pubmed